Vertex Pharma stock drops 5% after company predicts slower Q3
Global AntiFungal Agents Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Gilead, Kramer Labs - Research and Markets
Kroll Bond Rating Agency Assigns Preliminary Ratings to MSBAM 2016-C30
Nasdaq nails major support, S&P 500 holds the range
Nasdaq nails major support, S&P 500 holds the -2-
Decibel Therapeutics Expands Leadership Team
Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine
Options on this firm's blockbuster cost a little but pay off big.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.